Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study

NCT07243418 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

72

Enrollment

OTHER_GOV

Sponsor class

Conditions

CTIT-Chemotherapy Induced Thrombocytopenia
Breast Cancer

Interventions

DRUG: herombopag olamine tablets

Sponsor

Fujian Cancer Hospital